BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 24501689)

  • 1. Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma.
    Poussin K; Pilati C; Couchy G; Calderaro J; Bioulac-Sage P; Bacq Y; Paradis V; Leteurtre E; Sturm N; Ramos J; Guettier C; Bardier-Dupas A; Boulai A; Wendum D; Selves J; Izard T; Nault JC; Zucman-Rossi J
    Oncoimmunology; 2013 Dec; 2(12):e27090. PubMed ID: 24501689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations leading to constitutive active gp130/JAK1/STAT3 pathway.
    Pilati C; Zucman-Rossi J
    Cytokine Growth Factor Rev; 2015 Oct; 26(5):499-506. PubMed ID: 26188635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas.
    Pilati C; Amessou M; Bihl MP; Balabaud C; Nhieu JT; Paradis V; Nault JC; Izard T; Bioulac-Sage P; Couchy G; Poussin K; Zucman-Rossi J
    J Exp Med; 2011 Jul; 208(7):1359-66. PubMed ID: 21690253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression.
    Schaper F; Gendo C; Eck M; Schmitz J; Grimm C; Anhuf D; Kerr IM; Heinrich PC
    Biochem J; 1998 Nov; 335 ( Pt 3)(Pt 3):557-65. PubMed ID: 9794795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent chromosomal rearrangements of
    Bayard Q; Caruso S; Couchy G; Rebouissou S; Bioulac Sage P; Balabaud C; Paradis V; Sturm N; de Muret A; Guettier C; Bonsang B; Copie C; Letouzé E; Calderaro J; Imbeaud S; Nault JC; Zucman-Rossi J
    Gut; 2020 Sep; 69(9):1667-1676. PubMed ID: 31907296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mosaic IL6ST variant inducing constitutive GP130 cytokine receptor signaling as a cause of neonatal onset immunodeficiency with autoinflammation and dysmorphy.
    Materna-Kiryluk A; Pollak A; Gawalski K; Szczawinska-Poplonyk A; Rydzynska Z; Sosnowska A; Cukrowska B; Gasperowicz P; Konopka E; Pietrucha B; Grzywa TM; Banaszak-Ziemska M; Niedziela M; Skalska-Sadowska J; Stawiński P; Śladowski D; Nowis D; Ploski R
    Hum Mol Genet; 2021 Apr; 30(3-4):226-233. PubMed ID: 33517393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sepsis induces interleukin 6, gp130/JAK2/STAT3, and muscle wasting.
    Zanders L; Kny M; Hahn A; Schmidt S; Wundersitz S; Todiras M; Lahmann I; Bandyopadhyay A; Wollersheim T; Kaderali L; Luft FC; Birchmeier C; Weber-Carstens S; Fielitz J
    J Cachexia Sarcopenia Muscle; 2022 Feb; 13(1):713-727. PubMed ID: 34821076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual signaling role of the protein tyrosine phosphatase SHP-2 in regulating expression of acute-phase plasma proteins by interleukin-6 cytokine receptors in hepatic cells.
    Kim H; Baumann H
    Mol Cell Biol; 1999 Aug; 19(8):5326-38. PubMed ID: 10409724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Janus Kinase 2 Inhibitor AG490 Inhibits the STAT3 Signaling Pathway by Suppressing Protein Translation of gp130.
    Seo IA; Lee HK; Shin YK; Lee SH; Seo SY; Park JW; Park HT
    Korean J Physiol Pharmacol; 2009 Apr; 13(2):131-8. PubMed ID: 19885008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Constitutively active mutant gp130 receptor protein from inflammatory hepatocellular adenoma is inhibited by an anti-gp130 antibody that specifically neutralizes interleukin 11 signaling.
    Sommer J; Effenberger T; Volpi E; Waetzig GH; Bernhardt M; Suthaus J; Garbers C; Rose-John S; Floss DM; Scheller J
    J Biol Chem; 2012 Apr; 287(17):13743-51. PubMed ID: 22523320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An alternative pathway for STAT activation that is mediated by the direct interaction between JAK and STAT.
    Fujitani Y; Hibi M; Fukada T; Takahashi-Tezuka M; Yoshida H; Yamaguchi T; Sugiyama K; Yamanaka Y; Nakajima K; Hirano T
    Oncogene; 1997 Feb; 14(7):751-61. PubMed ID: 9047382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours.
    Rebouissou S; Amessou M; Couchy G; Poussin K; Imbeaud S; Pilati C; Izard T; Balabaud C; Bioulac-Sage P; Zucman-Rossi J
    Nature; 2009 Jan; 457(7226):200-4. PubMed ID: 19020503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRAF2 and TRAF5 associated with the signal transducing receptor gp130 limit IL-6-driven transphosphorylation of JAK1 through the inhibition of proximal JAK-JAK interaction.
    Kimura M; Nagashima H; Okuyama Y; Ishii N; So T
    Int Immunol; 2018 Jun; 30(7):291-299. PubMed ID: 29668931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells.
    De Vos J; Jourdan M; Tarte K; Jasmin C; Klein B
    Br J Haematol; 2000 Jun; 109(4):823-8. PubMed ID: 10929036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic deletion mutants of gp130 signal from intracellular compartments.
    Schmidt-Arras D; Müller M; Stevanovic M; Horn S; Schütt A; Bergmann J; Wilkens R; Lickert A; Rose-John S
    J Cell Sci; 2014 Jan; 127(Pt 2):341-53. PubMed ID: 24213527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of JAK-STAT and MAP kinases by leukemia inhibitory factor through gp130 in cardiac myocytes.
    Kunisada K; Hirota H; Fujio Y; Matsui H; Tani Y; Yamauchi-Takihara K; Kishimoto T
    Circulation; 1996 Nov; 94(10):2626-32. PubMed ID: 8921810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coactivation of janus tyrosine kinase (Jak)1 positively modulates prolactin-Jak2 signaling in breast cancer: recruitment of ERK and signal transducer and activator of transcription (Stat)3 and enhancement of Akt and Stat5a/b pathways.
    Neilson LM; Zhu J; Xie J; Malabarba MG; Sakamoto K; Wagner KU; Kirken RA; Rui H
    Mol Endocrinol; 2007 Sep; 21(9):2218-32. PubMed ID: 17550976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Jak1 plays an essential role for receptor phosphorylation and Stat activation in response to granulocyte colony-stimulating factor.
    Shimoda K; Feng J; Murakami H; Nagata S; Watling D; Rogers NC; Stark GR; Kerr IM; Ihle JN
    Blood; 1997 Jul; 90(2):597-604. PubMed ID: 9226159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of the IL-6-Signaling Pathway in Liver Cells by miRNAs Targeting gp130, JAK1, and/or STAT3.
    Servais FA; Kirchmeyer M; Hamdorf M; Minoungou NWE; Rose-John S; Kreis S; Haan C; Behrmann I
    Mol Ther Nucleic Acids; 2019 Jun; 16():419-433. PubMed ID: 31026677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of protein kinase II (CK2) prevents induced signal transducer and activator of transcription (STAT) 1/3 and constitutive STAT3 activation.
    Aparicio-Siegmund S; Sommer J; Monhasery N; Schwanbeck R; Keil E; Finkenstädt D; Pfeffer K; Rose-John S; Scheller J; Garbers C
    Oncotarget; 2014 Apr; 5(8):2131-48. PubMed ID: 24742922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.